

# Maj-Britt Jensen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/166519/maj-britt-jensen-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62  
papers

7,709  
citations

24  
h-index

64  
g-index

64  
ext. papers

8,897  
ext. citations

6.9  
avg, IF

5.15  
L-index

#	Paper	IF	Citations
62	Risk of ischemic heart disease in women after radiotherapy for breast cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 987-98	59.2	2180
61	Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 949-55	59.2	2073
60	Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. <i>Lancet, The</i> , <b>1999</b> , 353, 1641-8	40	1283
59	Prevalence of and factors associated with persistent pain following breast cancer surgery. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 1985-92	27.4	526
58	Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 100, 167-75	5.3	305
57	The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. <i>Acta Oncologica</i> , <b>2008</b> , 47, 506-24	3.2	216
56	Self-reported arm-lymphedema and functional impairment after breast cancer treatment--a nationwide study of prevalence and associated factors. <i>Breast</i> , <b>2010</b> , 19, 506-15	3.6	147
55	PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 735-740	2.2	71
54	HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 984-90	2.2	67
53	Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2288-2296	2.2	64
52	Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 123, 299-305	5.3	54
51	Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 877-84	7.5	49
50	Danish Breast Cancer Cooperative Group. <i>Clinical Epidemiology</i> , <b>2016</b> , 8, 445-449	5.9	48
49	Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 1363-72	9.7	40
48	Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 2201-6	7.5	35
47	The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016. <i>Acta Oncologica</i> , <b>2018</b> , 57, 13-18	3.2	35
46	Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2639-2646	2.2	34

45	Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG Registry. <i>Acta Oncologica</i> , <b>2008</b> , 47, 525-36	3.2	34
44	Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: a nationwide study. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 872-8	7.5	30
43	Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment. <i>Acta Oncologica</i> , <b>2016</b> , 55 Suppl 2, 24-35	3.2	29
42	The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. <i>Breast Cancer Research</i> , <b>2018</b> , 20, 79	8.3	29
41	Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1447-1453	12.3	26
40	Influence of specific comorbidities on survival after early-stage breast cancer. <i>Acta Oncologica</i> , <b>2018</b> , 57, 129-134	3.2	25
39	Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. <i>Acta Oncologica</i> , <b>2014</b> , 53, 174-85	3.2	25
38	Incidence of metachronous contralateral breast cancer in Denmark 1978-2009. <i>International Journal of Epidemiology</i> , <b>2014</b> , 43, 1855-64	7.8	24
37	Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1412-21	7.5	19
36	Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977-2005. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 152, 103-110	5.3	18
35	Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 223-9	4.4	18
34	Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. <i>Cancer</i> , <b>2010</b> , 116, 2081-9	6.4	17
33	Is DBCG abreast of new developments?. <i>Acta Oncologica</i> , <b>2018</b> , 57, 1-2	3.2	15
32	Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 153, 599-606	4.4	13
31	Risk of contralateral breast cancer after tamoxifen use among Danish women. <i>Annals of Epidemiology</i> , <b>2014</b> , 24, 843-8	6.4	13
30	CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 163-9	4.4	13
29	Risk factors of sentinel and non-sentinel lymph node metastases in patients with ductal carcinoma in situ of the breast: A nationwide study. <i>Breast</i> , <b>2018</b> , 42, 128-132	3.6	12
28	Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 46	8.3	11

27	The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. <i>European Journal of Cancer</i> , <b>2017</b> , 87, 1-9	7.5	10
26	Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. <i>Acta Oncologica</i> , <b>2018</b> , 57, 3-12	3.2	10
25	The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 7	7.8	9
24	Breast cancer in situ. From pre-malignant lesion of uncertain significance to well-defined non-invasive malignant lesion. The Danish Breast Cancer Cooperative Group Register 1977-2007 revisited. <i>Acta Oncologica</i> , <b>2008</b> , 47, 765-71	3.2	8
23	Molecular subtyping of breast cancer improves identification of both high and low risk patients. <i>Acta Oncologica</i> , <b>2018</b> , 57, 58-66	3.2	8
22	Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 175, 713-719	4.4	6
21	Risk of pacemaker or implantable cardioverter defibrillator after radiotherapy for early-stage breast cancer in Denmark, 1982-2005. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 122, 60-65	5.3	6
20	Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. <i>Preventive Medicine</i> , <b>2018</b> , 116, 186-193	4.3	6
19	Axillary lymph node dissection in breast cancer patients after sentinel node biopsy. <i>Acta Oncologica</i> , <b>2018</b> , 57, 166-169	3.2	5
18	Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG). <i>Breast</i> , <b>2020</b> , 54, 242-247	3.6	4
17	Adherence to treatment guidelines and survival in older women with early-stage breast cancer in Denmark 2008-2012. <i>Acta Oncologica</i> , <b>2020</b> , 59, 741-747	3.2	4
16	Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients. <i>Breast</i> , <b>2020</b> , 51, 34-39	3.6	4
15	The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1102-1108	8.7	4
14	Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials. <i>Acta Oncologica</i> , <b>2018</b> , 57, 135-140	3.2	4
13	Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 1388-1398	8.7	4
12	The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study. <i>Acta Oncologica</i> , <b>2018</b> , 57, 141-145	3.2	3
11	Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 184, 123-133	4.4	2
10	Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers. <i>Acta Oncologica</i> , <b>2016</b> , 55, 455-9	3.2	2

9	Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status. <i>Scientific Reports</i> , <b>2021</b> , 11, 2259	4.9	2
8	Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial. <i>Acta Oncologica</i> , <b>2018</b> , 57, 26-30	3.2	2
7	Provision of data from the clinical database and of biological material from the tumor bank of the Danish Breast Cancer Cooperative Group 2008-2017. <i>Acta Oncologica</i> , <b>2018</b> , 57, 154-156	3.2	2
6	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. <i>Oncolmunology</i> , <b>2021</b> , 10, 1924492	7.2	2
5	Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1421-1428	12.9	1
4	Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 516-517	2.2	1
3	Association between early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women in a Danish population-based cohort		1
2	Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1608-1615	8.7	1
1	First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG.. <i>Breast Cancer: Basic and Clinical Research</i> , <b>2022</b> , 16, 1178223422108692	2.2	